Want to see LONA full AI Analyst Report?
Top Page
LeonaBio
(NASDAQ:LONA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$8.00
▼(-9.71% Downside)
Action:Reiterated
Date:06/24/26
The score is primarily constrained by weak financial performance (no revenue, large and worsening losses, and meaningful ongoing cash burn with a much smaller equity base), which increases future financing/dilution risk. Technicals also lean bearish with price below key moving averages and a negative MACD. Corporate events provide some support via pipeline progress targets and financing-related updates, but they do not fully offset the current loss-making and cash-consuming profile; valuation metrics are limited due to negative earnings and no dividend.
Positive Factors
Strengthened Oncology Pipeline
Licensing lasofoxifene and scaling ELAINE-3 to ~600 patients materially enhances LeonaBio's oncology pipeline and regulatory-readiness. A larger Phase 3 raises potential commercial opportunity in ER+/HER2- ESR1-mutant metastatic breast cancer and supports long-term revenue potential if trials succeed.
Negative Factors
Pre-Revenue with Growing Losses
LeonaBio remains pre-revenue and incurred materially larger TTM losses, meaning the business lacks internal revenue cushions. Persisting negative earnings structurally increases dependency on external funding and heightens execution risk for clinical programs over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened Oncology Pipeline
Licensing lasofoxifene and scaling ELAINE-3 to ~600 patients materially enhances LeonaBio's oncology pipeline and regulatory-readiness. A larger Phase 3 raises potential commercial opportunity in ER+/HER2- ESR1-mutant metastatic breast cancer and supports long-term revenue potential if trials succeed.
Read all positive factors
LeonaBio (LONA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$88.30M
Dividend YieldN/A
Average Volume (3M)41.47K
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue GrowthN/A
EPS Growth-16.62%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-30.13
Shares Outstanding9,393,514
10 Day Avg. Volume36,543
30 Day Avg. Volume41,474
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.71
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.00Price Target Upside103.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.57
Revenue Forecast (FY)N/A
LeonaBio Business Overview & Revenue Model
Company Description
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegener...
LeonaBio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -68.53M | -68.09M | 0.00 | 0.00 | 0.00 | -479.00K |
| EBITDA | -108.81M | -101.62M | -95.81M | -125.97M | -88.01M | -54.37M |
| Net Income | -129.41M | -105.61M | -96.94M | -117.67M | -95.64M | -54.85M |
Balance Sheet | ||||||
| Total Assets | 71.59M | 92.15M | 58.78M | 160.25M | 258.15M | 332.01M |
| Cash, Cash Equivalents and Short-Term Investments | 67.68M | 88.33M | 51.27M | 147.42M | 200.34M | 253.76M |
| Total Debt | 691.00K | 803.00K | 1.22M | 1.58M | 1.91M | 1.92M |
| Total Liabilities | 22.29M | 64.36M | 13.94M | 30.06M | 23.02M | 10.92M |
| Stockholders Equity | 49.30M | 27.79M | 44.84M | 130.19M | 235.14M | 321.08M |
Cash Flow | ||||||
| Free Cash Flow | -51.97M | -45.73M | -97.20M | -101.06M | -73.61M | -44.67M |
| Operating Cash Flow | -51.97M | -45.73M | -97.17M | -100.75M | -72.47M | -43.10M |
| Investing Cash Flow | -24.08M | -15.89M | 54.83M | 95.09M | 57.66M | -4.08M |
| Financing Cash Flow | 82.46M | 82.46M | 194.00K | 493.00K | 654.00K | 97.09M |
LeonaBio Technical Analysis
Positive
8.86
Price Trends
9.16
Positive
8.28
Positive
6.54
Positive
Market Momentum
-0.18
Negative
58.42
Neutral
62.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LONA, the sentiment is Positive. The current price of 8.86 is above the 20-day moving average (MA) of 8.58, below the 50-day MA of 9.16, and above the 200-day MA of 6.54, indicating a bullish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 58.42 is Neutral, neither overbought nor oversold. The STOCH value of 62.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LONA.
LeonaBio Risk Analysis
LeonaBio disclosed 89 risk factors in its most recent earnings report. LeonaBio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LeonaBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $20.14M | -0.34 | -248.91% | ― | ― | 58.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $88.30M | -0.31 | -381.01% | ― | ― | -16.62% | |
45 Neutral | $14.06M | -1.38 | -94.94% | ― | ― | 53.06% | |
44 Neutral | $7.65M | -1.82 | -49.00% | ― | 11.90% | 43.46% | |
| ― | $14.63M | -1.32 | -94.79% | ― | ― | 79.70% |
* Healthcare Sector Average
LONA
LeonaBio
9.40
6.38
211.26%
CLRB
Cellectar Biosciences
2.52
-4.59
-64.56%
IMRN
Immuron
1.10
-0.64
-36.78%
COCP
Cocrystal Pharma
1.02
-0.47
-31.54%
BIVI
BioVie
1.94
-7.31
-79.03%
LeonaBio Corporate Events
Executive/Board ChangesShareholder Meetings
LeonaBio Shareholders Approve Directors, Auditor and Compensation
Positive
Jun 23, 2026
On June 22, 2026, LeonaBio held its 2026 Annual Meeting of Stockholders, with approximately 84.19% of eligible shares present or represented by proxy, establishing a quorum for business. Stockholders elected three Class III directors, Kelly A. Rom...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
LeonaBio Updates Investors on 2025 Results and Strategy
Positive
Mar 26, 2026
On March 26, 2026, LeonaBio, Inc. released an updated investor presentation alongside full-year 2025 results, highlighting its transformation into a more focused biopharmaceutical company following a rebrand from Athira Pharma and the acquisition ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.